2. UroToday Home
  3. Center Of Excellence
  4. mCRPC Treatment
Back to mCRPC Treatment

Progress and Promise in Prostate Cancer

Advances in mCRPC Management: Recent Approvals, Emerging Therapies, and Future Directions: A Letter from UroToday's mCRPC Center of Excellence Editor-in-Chief, A. Oliver Sartor, MD

I am delighted to serve as the new editor for UroToday’s Center of Excellence on mCRPC Treatment. We provide a multimedia, data-driven hub for information on regulatory approvals, clinical trials, diagnostics, guidelines, investigational treatments, and other aspects of this rapidly evolving field. In this editorial, I cover recent therapeutic approvals in mCRPC, clinical trials, and investigational therapies.

Prostate cancer is the second leading cancer and the most common cause of cancer-related mortality in men, resulting in approximately 397,000 deaths globally in 2022.1 Metastatic castration-resistant prostate cancer (mCRPC) is the final and most aggressive stage of disease, and its prevalence is rising.2,3 Currently, median survival after diagnosis of mCRPC is just over 2 years.4,5 Progressive, symptomatic mCRPC greatly diminishes patients’ functioning and quality of life, and its management consumes significant healthcare resources, making thoughtful clinical decision-making imperative.